UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 58

Sortiert nach

Roles of the Polycomb group proteins in stem cells and cancer

Cell death & disease, 2011-09, Vol.2 (9), p.e204-e204

2011

Link zum Volltext

Verfügbarkeit prüfen

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

British journal of cancer, 2012-05, Vol.106 (11), p.1722-1727

2012

Link zum Volltext

Verfügbarkeit prüfen

A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer

European journal of cancer (1990), 2015-01, Vol.51 (1), p.27-36

2015

Link zum Volltext

Verfügbarkeit prüfen

A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV

European journal of cancer (1990), 2015-01, Vol.51 (1), p.27

2015

Link zum Volltext

Verfügbarkeit prüfen

ZRF1 controls oncogene-induced senescence through the INK4-ARF locus

Oncogene, 2013-04, Vol.32 (17), p.2161-2168

2013

Link zum Volltext

Verfügbarkeit prüfen

Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial

European journal of cancer (1990), 2009-03, Vol.45 (4), p.579-587

2009

Link zum Volltext

Verfügbarkeit prüfen

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

Annals of oncology, 2006-05, Vol.17 (5), p.866-873

2006

Link zum Volltext

Verfügbarkeit prüfen

A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer

Breast cancer research and treatment, 2013-07, Vol.140 (2), p.331-339

2013

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis

International journal of clinical pharmacology and therapeutics, 2009-01, Vol.47 (1), p.61

2009

Link zum Volltext

Verfügbarkeit prüfen

PP 51 Register trial of sorafenib (S) for patients (pts) with metastatic uveal melanoma (metUvMel)

European journal of cancer (1990), 2011, Vol.47, p.S30-S30

2011

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors

International journal of clinical pharmacology and therapeutics, 2009-01, Vol.47 (1), p.58

2009

Link zum Volltext

Verfügbarkeit prüfen

A Series of Ubiquitin Binding Factors Connects CDC48/p97 to Substrate Multiubiquitylation and Proteasomal Targeting

Cell, 2005-01, Vol.120 (1), p.73-84

2005

Link zum Volltext

Verfügbarkeit prüfen

Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx/Doxil in patients with hematological tumors

International journal of clinical pharmacology and therapeutics, 2009-01, Vol.47 (1), p.55

2009

Link zum Volltext

Verfügbarkeit prüfen

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

Journal of clinical oncology, 2005-02, Vol.23 (5), p.965-972

2005

Link zum Volltext

Verfügbarkeit prüfen

Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors

International journal of clinical pharmacology and therapeutics, 2002-12, Vol.40 (12), p.580

2002

Link zum Volltext

Verfügbarkeit prüfen

Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer

International journal of clinical pharmacology and therapeutics, 2004-11, Vol.42 (11), p.650

2004

Link zum Volltext

Verfügbarkeit prüfen

Mobilization of processed, membrane-tethered SPT23 transcription factor by CDC48(UFD1/NPL4), a ubiquitin-selective chaperone

Cell, 2001-11, Vol.107 (5), p.667-677

2001

Link zum Volltext

Verfügbarkeit prüfen

Shp1 and Ubx2 are adaptors of Cdc48 involved in ubiquitin-dependent protein degradation

EMBO reports, 2004-08, Vol.5 (8), p.818-824

2004

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/Doxil

International journal of clinical pharmacology and therapeutics, 2005-12, Vol.43 (12), p.588

2005

Link zum Volltext

Verfügbarkeit prüfen

A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors

Annals of oncology, 2004-08, Vol.15 (8), p.1284-1294

2004

Link zum Volltext

Verfügbarkeit prüfen

A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors

International journal of clinical pharmacology and therapeutics, 2003-12, Vol.41 (12), p.620

2003

Link zum Volltext

Verfügbarkeit prüfen

496 A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered day 1 and 15 every four weeks, in patients with advanced solid tumours

European journal of cancer supplements, 2010, Vol.8 (7), p.158-159

2010

Link zum Volltext

Verfügbarkeit prüfen

50 A phase I study of the safety, tolerability and pharmacokinetics of pazopanib (P) in combination with gemcitabine (G) for advanced solid tumors

European journal of cancer supplements, 2010, Vol.8 (7), p.25-25

2010

Link zum Volltext

Verfügbarkeit prüfen

Anti-tumor activity of the pan-FGFR inhibitor rogaratinib in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levels

Annals of oncology, 2017-09, Vol.28, p.v302-v302

2017

Link zum Volltext

Verfügbarkeit prüfen

A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study

Annals of oncology, 2017-09, Vol.28, p.v126-v127

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(49)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(21)
Science & Technology
(18)
Life Sciences & Biomedicine
(16)
Female
(12)
Middle Aged
(12)
Oncology
(11)
Adult
(10)
Aged
(10)
Male
(10)
Biological And Medical Sciences
(9)
Medical Sciences
(9)
Hematology, Oncology And Palliative Medicine
(8)
Dose-Response Relationship, Drug
(7)
Niacinamide - Analogs & Derivatives
(7)
Phenylurea Compounds
(7)
Tumors
(7)
Doxorubicin - Administration & Dosage
(6)
Sorafenib
(6)
Antineoplastic Agents
(5)
Antineoplastic Agents - Administration & Dosage
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Roles of the Polycomb group proteins in stem cells and cancer

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer

A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV

ZRF1 controls oncogene-induced senescence through the INK4-ARF locus

Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer

Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis

PP 51 Register trial of sorafenib (S) for patients (pts) with metastatic uveal melanoma (metUvMel)

Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors

A Series of Ubiquitin Binding Factors Connects CDC48/p97 to Substrate Multiubiquitylation and Proteasomal Targeting

Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx/Doxil in patients with hematological tumors

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors

Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer

Mobilization of processed, membrane-tethered SPT23 transcription factor by CDC48(UFD1/NPL4), a ubiquitin-selective chaperone

Shp1 and Ubx2 are adaptors of Cdc48 involved in ubiquitin-dependent protein degradation

Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/Doxil

A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors

A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors

496 A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered day 1 and 15 every four weeks, in patients with advanced solid tumours

50 A phase I study of the safety, tolerability and pharmacokinetics of pazopanib (P) in combination with gemcitabine (G) for advanced solid tumors

Anti-tumor activity of the pan-FGFR inhibitor rogaratinib in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levels

A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study

Suchergebnisse filtern